ArticleCureus2025
Efficacy and Safety of 5 µg and 10 µg Dexmedetomidine With Hyperbaric Levobupivacaine in Lower-Limb Surgeries Under Spinal Anesthesia: A Randomized Controlled Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDexmedetomidine is used as an intrathecal adjuvant to enhance the quality and duration of spinal anesthesia (SA). However, the extent to which different intrathecal doses affect the characteristics of the block and hemodynamic responses remains unclear.
objectiveTo compare the efficacy and safety of intrathecal 5 µg versus 10 µg dexmedetomidine added to 0.5% hyperbaric levobupivacaine in patients undergoing lower-limb surgery.
methods60 American Society of Anesthesiologists (ASA) I-II adults scheduled for elective lower-limb orthopedic and soft-tissue procedures were randomized into two groups. Group D5 received 5 µg dexmedetomidine, and Group D10 received 10 µg intrathecally with hyperbaric levobupivacaine. Sensory and motor block characteristics were assessed every three minutes until maximum levels were achieved. Hemodynamic parameters, including heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean arterial pressure (MAP), were monitored at predefined intervals. The primary outcome was the duration of sensory block; secondary outcomes included onset time, motor block duration, and intraoperative hemodynamic changes.
resultsGroup D10 reached maximum sensory block (3.65 ± 1.15 vs. 4.40 ± 1.22 min; p = 0.017) and maximum motor block (6.05 ± 1.30 vs. 7.90 ± 2.12 min; p = 0.0001) significantly faster than Group D5. The duration of sensory block was also longer in Group D10. Bradycardia and hypotension occurred more frequently in Group D10 but were transient and managed without complications.
conclusionBoth doses enhanced SA characteristics. The 10 µg dose produced faster onset and longer duration of block but with a higher incidence of manageable hemodynamic effects. Selection of dose should balance the need for prolonged anesthesia with safety considerations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.